Adrenal insufficiency | Nature Reviews Disease Primers

  1. 1. Arlt, W. & Allolio, B. Adrenal insufficiency. Lancet 361, 1881–1893 ( 2003 ) .
  2. 2. Ross, I. L. & Levitt, N. S. Addison ’ s disease symptoms–a intersect sectional cogitation in urban South Africa. PLoS ONE 8, e53526 ( 2013 ).
  3. 3. Erichsen, M. M. et aluminum. Clinical, immunological, and genetic features of autoimmune primary adrenal gland insufficiency : observations from a norwegian register. J. Clin. Endocrinol. Metab. 94, 4882–4890 ( 2009 ) .
  4. 4. Afreen, B., Khan, K. A. & Riaz, A. Adrenal insufficiency in Pakistani HIV infected patients. J. Ayub Med. Coll. Abbottabad 29, 428–431 ( 2017 ) .
  5. 5. Mofokeng, T. R. P., Beshyah, S. A., Mahomed, F., Ndlovu, K. C. Z. & Ross, I. L. Significant barriers to diagnosis and management of adrenal insufficiency in Africa. Endocr. Connect. 9, 445–456 ( 2020 ) .
  6. 6. Odeniyi, I. A., Fasanmade, O. A., Ajala, M. O. & Ohwovoriole, A. E. Adrenocortical function in Nigerians with human immunodeficiency virus infection. Ghana. Med. J. 47, 171–177 ( 2013 ) .
  7. 7. Tripathy, S. K., Agrawala, R. K. & Baliarsinha, A. K. Endocrine alterations in HIV-infected patients. Indian. J. Endocrinol. Metab. 19, 143–147 ( 2015 ) .
  8. 8. Broersen, L. H., Pereira, A. M., Jorgensen, J. O. & Dekkers, O. M. Adrenal insufficiency in corticosteroids use : systematic inspection and meta-analysis. J. Clin. Endocrinol. Metab. 100, 2171–2180 ( 2015 ) .
  9. 9. Bleicken, B., Hahner, S., Ventz, M. & Quinkler, M. Delayed diagnosis of adrenal insufficiency is common : a cross-section study in 216 patients. Am. J. Med. Sci. 339, 525–531 ( 2010 ) .
  10. 10. Allolio, B. across-the-board expertness in endocrinology adrenal gland crisis. Eur. J. Endocrinol. 172, R115–R124 ( 2015 ) .
  11. 11. Hahner, S. et alabama. high incidence of adrenal crisis in educate patients with chronic adrenal insufficiency : a prospective survey. J. Clin. Endocrinol. Metab. 100, 407–416 ( 2015 ) .
  12. 12. Puar, T. H., Stikkelbroeck, N. M., Smans, L. C., Zelissen, P. M. & Hermus, A. R. Adrenal crisis : still a deadly event in the twenty-first century. Am. J. Med. 129, 339 e331–339 e339 ( 2016 ) .
  13. 13. Rushworth, R. L., Torpy, D. J. & Falhammar, H. Adrenal crises : perspectives and research directions. Endocrine 55, 336–345 ( 2017 ) .
  14. 14. Smans, L. C., Van five hundred Valk, E. S., Hermus, A. R. & Zelissen, P. M. Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. 84, 17–22 ( 2016 ) .
  15. 15. Bornstein, S. R. et alabama. Diagnosis and treatment of elementary adrenal insufficiency : an Endocrine Society clinical rehearse road map. J. Clin. Endocrinol. Metab. 101, 364–389 ( 2016 ). Practice guidelines on the management of adrenal insufficiency from an international expert panel .
  16. 16. Dunlop, D. Eighty-six cases of Addison ’ sulfur disease. Br. Med. J. 2, 887–891 ( 1963 ) .
  17. 17. Laureti, S., Vecchi, L., Santeusanio, F. & Falorni, A. Is the prevalence of Addison ’ s disease underestimated ? J. Clin. Endocrinol. Metab. 84, 1762 ( 1999 ) .
  18. 18. Hellesen, A., Bratland, E. & Husebye, E. S. Autoimmune Addison ’ s disease – an update on pathogenesis. Ann. Endocrinol. 79, 157–163 ( 2018 ) .
  19. 19. Mason, A. S., Meade, T. W., Lee, J. A. & Morris, J. N. Epidemiological and clinical mental picture of Addison ’ randomness disease. Lancet 2, 744–747 ( 1968 ) .
  20. 20. Olafsson, A. S. & Sigurjonsdottir, H. A. Increasing preponderance of Addison disease : results from a countrywide survey. Endocr. Pract. 22, 30–35 ( 2016 ) .
  21. 21. Bjornsdottir, S. et alabama. Drug prescription patterns in patients with Addison ’ south disease : a swedish population-based age group analyze. J. Clin. Endocrinol. Metab. 98, 2009–2018 ( 2013 ) .
  22. 22. Meyer, G., Neumann, K., Badenhoop, K. & Linder, R. Increasing prevalence of Addison ’ randomness disease in german females : health indemnity data 2008-2012. Eur. J. Endocrinol. 170, 367–373 ( 2014 ) .
  23. 23. Stewart, P. M. et alabama. Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency. J. Clin. Endocrinol. Metab. 101, 4843–4850 ( 2016 ) .
  24. 24. Willis, A. C. & Vince, F. P. The prevalence of Addison ’ s disease in Coventry, UK. Postgrad. Med. J. 73, 286–288 ( 1997 ) .
  25. 25. Chantzichristos, D. et aluminum. Incidence, prevalence and seasonal worker attack variation of Addison ’ mho disease among persons with type 1 diabetes mellitus : nationally, match cohort studies. Eur. J. Endocrinol. 178, 113–120 ( 2018 ). A nationwide, matched, observational cohort study investigating the incidence and prevalence of primary adrenal insufficiency in Sweden .
  26. 26. Betterle, C., Dal Pra, C., Mantero, F. & Zanchetta, R. Autoimmune adrenal gland insufficiency and autoimmune polyendocrine syndromes : autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev. 23, 327–364 ( 2002 ) .
  27. 27. Laureti, S. et aluminum. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison ’ south disease. J. Clin. Endocrinol. Metab. 83, 3507–3511 ( 1998 ) .
  28. 28. Herndon, J., Nadeau, A. M., Davidge-Pitts, C. J., Young, W. F. & Bancos, I. primary adrenal gland insufficiency ascribable to bilateral infiltrative disease. Endocrine 62, 721–728 ( 2018 ) .
  29. 29. Merke, D. P. & Auchus, R. J. Congenital adrenal hyperplasia due to 21-hydroxylase lack. N. Engl. J. Med. 383, 1248–1261 ( 2020 ) .
  30. 30. White, P. C. & Speiser, P. W. Congenital adrenal hyperplasia due to 21-hydroxylase lack. Endocr. Rev. 21, 245–291 ( 2000 ) .
  31. 31. Bancos, I., Hahner, S., Tomlinson, J. & Arlt, W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 3, 216–226 ( 2015 ) .
  32. 32. Michels, A. W. & Gottlieb, P. A. Autoimmune polyglandular syndromes. Nat. Rev. Endocrinol. 6, 270–277 ( 2010 ) .
  33. 33. Husebye, E. S., Anderson, M. S. & Kampe, O. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 378, 2543–2544 ( 2018 ) .
  34. 34. Dalin, F. et aluminum. clinical and immunological characteristics of autoimmune Addison disease : a nationally Swedish multicenter study. J. Clin. Endocrinol. Metab. 102, 379–389 ( 2017 ) .
  35. 35. Reato, G. et alabama. Premature ovarian failure in patients with autoimmune Addison ’ second disease : clinical, genic, and immunological evaluation. J. Clin. Endocrinol. Metab. 96, E1255–E1261 ( 2011 ) .
  36. 36. Charmandari, E., Nicolaides, N. C. & Chrousos, G. P. Adrenal insufficiency. Lancet 383, 2152–2167 ( 2014 ) .
  37. 37. Regal, M., Paramo, C., Sierra, S. M. & Garcia-Mayor, R. V. Prevalence and incidence of hypopituitarism in an adult caucasian population in northwestern Spain. Clin. Endocrinol. 55, 735–740 ( 2001 ) .
  38. 38. Bates, A. S., Van ’ t Hoff, W., Jones, P. J. & Clayton, R. N. The effect of hypopituitarism on life anticipation. J. Clin. Endocrinol. Metab. 81, 1169–1172 ( 1996 ) .
  39. 39. Tomlinson, J. W. et alabama. Association between previous deathrate and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425–431 ( 2001 ). A prospective study including 1,014 patients with hypopituitarism investigating the total and specific-cause mortality compared with an age-matched and sex-matched UK population .
  40. 40. Carosi, G. et alabama. Hypothalamic-pituitary axis in non-functioning pituitary adenoma : concenter on the preponderance of isolate central addison’s disease. Neuroendocrinology 102, 267–273 ( 2015 ) .
  41. 41. Appelman-Dijkstra, N. M. et aluminum. pituitary dysfunction in pornographic patients after cranial radiotherapy : taxonomic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 2330–2340 ( 2011 ) .
  42. 42. Jenkins, P. J., Bates, P., Carson, M. N., Stewart, P. M. & Wass, J. A. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J. Clin. Endocrinol. Metab. 91, 1239–1245 ( 2006 ) .
  43. 43. Knappe, U. J. et aluminum. Fractionated radiotherapy and radiosurgery in acromegaly : psychoanalysis of 352 patients from the german Acromegaly Registry. Eur. J. Endocrinol. 182, 275–284 ( 2020 ) .
  44. 44. Imber, B. S., Lee, H. S., Kunwar, S., Blevins, L. S. & Aghi, M. K. Hypophysitis : a single-center case series. Pituitary 18, 630–641 ( 2015 ) .
  45. 45. Wang, S. et alabama. Primary lymphocytic hypophysitis : clinical characteristics and treatment of 50 cases in a single centre in China over 18 years. Clin. Endocrinol. 87, 177–184 ( 2017 ) .
  46. 46. Turcu, A. F. et alabama. pituitary chaff lesions : the Mayo Clinic experience. J. Clin. Endocrinol. Metab. 98, 1812–1818 ( 2013 ) .
  47. 47. Lu, J., Li, L., Lan, Y., Liang, Y. & Meng, H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction : a systematic reappraisal and meta-analysis. Cancer Med. 8, 7503–7515 ( 2019 ) .
  48. 48. Barroso-Sousa, R. et aluminum. incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens : a taxonomic reappraisal and meta-analysis. JAMA Oncol. 4, 173–182 ( 2018 ) .
  49. 49. Chang, L. S. et aluminum. Endocrine perniciousness of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17–65 ( 2019 ) .
  50. 50. Li, T. et alabama. prevalence of opioid-induced adrenal insufficiency in patients taking chronic opioids. J. Clin. Endocrinol. Metab. 105, e3766–e3775 ( 2020 ) .
  51. 51. de Vries, F. et alabama. Opioids and their endocrine effects : a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, 1020–1029 ( 2020 ) .
  52. 52. Saeed, Z. I., Bancos, I. & Donegan, D. Current cognition and practices of heath care professionals on opioid-induced adrenal insufficiency. Endocr. Pract. 25, 1012–1021 ( 2019 ) .
  53. 53. Woods, C. P. et aluminum. adrenal suppression in patients taking inhale glucocorticoids is highly prevailing and management can be guided by dawn hydrocortisone. Eur. J. Endocrinol. 173, 633–642 ( 2015 ) .
  54. 54. Schlaghecke, R., Kornely, E., Santen, R. T. & Ridderskamp, P. The consequence of long-run glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N. Engl. J. Med. 326, 226–230 ( 1992 ) .
  55. 55. Mebrahtu, T. F. et aluminum. Dose colony of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality : a cohort study in England. J. Clin. Endocrinol. Metab. 104, 3757–3767 ( 2019 ) .
  56. 56. Pofi, R. et aluminum. The unretentive Synacthen ( adrenocorticotropic hormone ) trial can be used to predict convalescence of hypothalamo-pituitary-adrenal bloc function. J. Clin. Endocrinol. Metab. 103, 3050–3059 ( 2018 ). A retrospective analysis of 776 patients with reversible causes of AI who had at least two short Synacthen tests performed to predict recovery of HPA axis function .
  57. 57. Joseph, R. M., Hunter, A. L., Ray, D. W. & Dixon, W. G. Systemic glucocorticoid therapy and adrenal insufficiency in adults : a systematic reappraisal. Semin. Arthritis Rheum. 46, 133–141 ( 2016 ) .
  58. 58. Leong, S. H., Shander, S. & Ratnasingam, J. Predicting convalescence of the hypothalamic-pituitary-adrenal axis after elongated glucocorticoid manipulation. Endocr. Pract. 24, 14–20 ( 2018 ) .
  59. 59. Odenwald, B. et alabama. Children with classical congenital adrenal hyperplasia experience salt loss and hypoglycemia : evaluation of adrenal crises during the first 6 years of life. Eur. J. Endocrinol. 174, 177–186 ( 2016 ) .
  60. 60. Reisch, N. et aluminum. frequency and causes of adrenal crises over life in patients with 21-hydroxylase insufficiency. Eur. J. Endocrinol. 167, 35–42 ( 2012 ) .
  61. 61. Ritzel, K. et alabama. clinical review : result of bilateral adrenalectomy in Cushing ’ s syndrome : a systematic recapitulation. J. Clin. Endocrinol. Metab. 98, 3939–3948 ( 2013 ) .
  62. 62. Meyer, G., Badenhoop, K. & Linder, R. Addison ’ s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises : german health indemnity data 2010-2013. Clin. Endocrinol. 85, 347–353 ( 2016 ) .
  63. 63. Papierska, L. & Rabijewski, M. Delay in diagnosis of adrenal gland insufficiency is a frequent cause of adrenal crisis. Int. J. Endocrinol. 2013, 482370 ( 2013 ) .
  64. 64. Gidlof, S. et aluminum. One hundred years of congenital adrenal hyperplasia in Sweden : a retrospective, population-based cohort study. Lancet Diabetes Endocrinol. 1, 35–42 ( 2013 ) .
  65. 65. Bergthorsdottir, R., Leonsson-Zachrisson, M., Oden, A. & Johannsson, G. Premature deathrate in patients with Addison ’ sulfur disease : a population-based cogitation. J. Clin. Endocrinol. Metab. 91, 4849–4853 ( 2006 ). A population-based, retrospective, observational study from Sweden showing that the risk ratio for death is more than twofold higher in patients with Addison disease than in the background population .
  66. 66. Bensing, S. et aluminum. Increased end hazard and altered cancer incidence blueprint in patients with detached or combined autoimmune primary adrenocortical insufficiency. Clin. Endocrinol. 69, 697–704 ( 2008 ) .
  67. 67. Erichsen, M. M. et alabama. Normal overall mortality rate in Addison ’ s disease, but unseasoned patients are at hazard of previous death. Eur. J. Endocrinol. 160, 233–237 ( 2009 ) .
  68. 68. Falhammar, H. et alabama. Increased deathrate in patients with congenital adrenal hyperplasia due to 21-hydroxylase lack. J. Clin. Endocrinol. Metab. 99, E2715–E2721 ( 2014 ) .
  69. 69. Hahner, S. et alabama. Epidemiology of adrenal gland crisis in chronic adrenal insufficiency : the need for new prevention strategies. Eur. J. Endocrinol. 162, 597–602 ( 2010 ) .
  70. 70. El-Maouche, D. et alabama. longitudinal appraisal of illnesses, tension dose, and illness sequela in patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 103, 2336–2345 ( 2018 ) .
  71. 71. Rushworth, R. L., Chrisp, G. L., Dean, B., Falhammar, H. & Torpy, D. J. Hospitalisation in children with adrenal insufficiency and hypopituitarism : is there a derived function load between boys and girls and between age groups ? Horm. Res. Paediatr. 88, 339–346 ( 2017 ) .
  72. 72. Rushworth, R. L., Falhammar, H., Munns, C. F., Maguire, A. M. & Torpy, D. J. Hospital entree patterns in children with CAH : entree rates and adrenal crises decline with age. Int. J. Endocrinol. 2016, 5748264 ( 2016 ) .
  73. 73. Rushworth, R. L. & Torpy, D. J. A descriptive study of adrenal crises in adults with adrenal gland insufficiency : increased risk with age and in those with bacterial infections. BMC Endocr. Disord. 14, 79 ( 2014 ) .
  74. 74. Rushworth, R. L. & Torpy, D. J. Modern hydrocortisone substitution regimens in adrenal insufficiency patients and the risk of adrenal gland crisis. Horm. Metab. Res. 47, 637–642 ( 2015 ) .
  75. 75. Rushworth, R. L. & Torpy, D. J. Adrenal insufficiency in Australia : is it possible that the use of lower venereal disease, short-acting glucocorticoids has increased the risk of adrenal gland crises ? Horm. Metab. Res. 47, 427–432 ( 2015 ) .
  76. 76. Okamoto, M. The metabolism of hydrocortisone in hyperthyroidism and Cushing ’ s syndrome. Endocrinol. Jpn. 10, 159–168 ( 1963 ) .
  77. 77. Fonseca, V., Brown, R., Hochhauser, D., Ginsburg, J. & Havard, C. W. Acute adrenal crisis precipitated by thyroxine. Br. Med. J. 292, 1185–1186 ( 1986 ) .
  78. 78. Rushworth, R. L., Chrisp, G. L. & Torpy, D. J. Glucocorticoid-induced adrenal insufficiency : a survey of the incidence in hospital patients and a review of peri-operative management. Endocr. Pract. 24, 437–445 ( 2018 ) .
  79. 79. Rushworth, R. L., Slobodian, P. & Torpy, D. J. Interruptions to supply of high-dose hydrocortisone tablets and the incidence of adrenal crises. Clin. Endocrinol. 83, 999–1000 ( 2015 ) .
  80. 80. Gjerstad, J. K., Lightman, S. L. & Spiga, F. Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility. Stress 21, 403–416 ( 2018 ) .
  81. 81. Lightman, S. L. & Conway-Campbell, B. L. The crucial function of pulsatile activeness of the HPA axis for continuous dynamic equilibration. Nat. Rev. Neurosci. 11, 710–718 ( 2010 ) .
  82. 82. Roelfsema, F., Aoun, P. & Veldhuis, J. D. Pulsatile cortisol feedback on ACTH secretion is mediated by the glucocorticoid sense organ and modulated by sex. J. Clin. Endocrinol. Metab. 101, 4094–4102 ( 2016 ) .
  83. 83. Walker, J. J., Terry, J. R. & Lightman, S. L. Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. Proc. Biol. Sci. 277, 1627–1633 ( 2010 ) .
  84. 84. Lightman, S. L., Birnie, M. T. & Conway-Campbell, B. L. Dynamics of ACTH and hydrocortisone secretion and implications for disease. Endocr. Rev. 41, 470–490 ( 2020 ) .
  85. 85. Oster, H. et alabama. The functional and clinical significance of the 24-hour rhythm method of birth control of circulating glucocorticoids. Endocr. Rev. 38, 3–45 ( 2017 ) .
  86. 86. Caratti, G. et aluminum. Glucocorticoid receptor serve in health and disease. Clin. Endocrinol. 83, 441–448 ( 2015 ) .
  87. 87. Chrousos, G. P. in Endocrinology 7th edition ( erectile dysfunction Jameson, J. L. & De Groot, L. ) 1727–1740.e5 ( Elsevier, 2016 ) .
  88. 88. Stavreva, D. A. et aluminum. Ultradian hormone foreplay induces glucocorticoid receptor-mediated pulses of gene transcription. Nat. Cell Biol. 11, 1093–1102 ( 2009 ). This study showed that an ultradian administration of glucocorticoids induces cyclic GR-mediated transcriptional regulation in cultured cells and in animal models .
  89. 89. Kalafatakis, K. et alabama. Ultradian rhythmicity of plasma hydrocortisone is necessity for normal emotional and cognitive responses in man. Proc. Natl Acad. Sci. USA 115, E4091–E4100 ( 2018 ) .
  90. 90. Chan, W. L., Carrell, R. W., Zhou, A. & Read, R. J. How changes in affinity of corticosteroid-binding globulin modulate unblock hydrocortisone concentration. J. Clin. Endocrinol. Metab. 98, 3315–3322 ( 2013 ) .
  91. 91. Henley, D., Lightman, S. & Carrell, R. Cortisol and CBG – Getting hydrocortisone to the right place at the right clock. Pharmacol. Ther. 166, 128–135 ( 2016 ) .
  92. 92. Stowasser, M., Ahmed, A. H., Pimenta, E., Taylor, P. J. & Gordon, R. D. Factors affecting the aldosterone/renin ratio. Horm. Metab. Res. 44, 170–176 ( 2012 ) .
  93. 93. Atlas, S. A. The renin-angiotensin aldosterone organization : pathophysiological character and pharmacological inhibition. J. Manag. Care Pharm. 13, 9–20 ( 2007 ) .
  94. 94. Tucci, J. R., Espiner, E. A., Jagger, P. I., Pauk, G. L. & Lauler, D. P. ACTH foreplay of aldosterone secretion in convention subjects and in patients with chronic adrenocortical insufficiency. J. Clin. Endocrinol. Metab. 27, 568–575 ( 1967 ) .
  95. 95. Kem, D. C. et alabama. Plasma aldosterone reaction to ACTH in elementary aldosteronism and in patients with broken renin high blood pressure. J. Clin. Endocrinol. Metab. 46, 552–560 ( 1978 ) .
  96. 96. Bollag, W. B. regulation of aldosterone deduction and secretion. Compr. Physiol. 4, 1017–1055 ( 2014 ) .
  97. 97. Mitchell, A. L. & Pearce, S. H. Autoimmune Addison disease : pathophysiology and genetic complexity. Nat. Rev. Endocrinol. 8, 306–316 ( 2012 ) .
  98. 98. Winqvist, O., Karlsson, F. A. & Kampe, O. 21-Hydroxylase, a major autoantigen in idiopathic Addison ’ s disease. Lancet 339, 1559–1562 ( 1992 ) .
  99. 99. Naletto, L. et aluminum. The natural history of autoimmune Addison ’ s disease from the detection of autoantibodies to development of the disease : a long follow-up study on 143 patients. Eur. J. Endocrinol. 180, 223–234 ( 2019 ) .
  100. 100. Dawoodji, A. et aluminum. high frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison ’ mho disease patients. J. Immunol. 193, 2118–2126 ( 2014 ) .
  101. 101. Bratland, E., Skinningsrud, B., Undlien, D. E., Mozes, E. & Husebye, E. S. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 94, 5117–5124 ( 2009 ) .
  102. 102. Eriksson, D. et aluminum. Common genic pas seul in the autoimmune regulator ( AIRE ) venue is associated with autoimmune Addison ’ sulfur disease in Sweden. Sci. Rep. 8, 8395 ( 2018 ) .
  103. 103. Skov, J. et aluminum. Heritability of Addison ’ mho disease and preponderance of consort autoimmunity in a cohort of 112,100 swedish twins. Endocrine 58, 521–527 ( 2017 ) .
  104. 104. Loeb, R. F. Chemical changes in the blood in Addison ’ s disease. Science 76, 420–421 ( 1932 ) .
  105. 105. Han, T. S., Walker, B. R., Arlt, W. & Ross, R. J. Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat. Rev. Endocrinol. 10, 115–124 ( 2014 ) .
  106. 106. Kemp, S., Huffnagel, I. C., Linthorst, G. E., Wanders, R. J. & Engelen, M. Adrenoleukodystrophy – neuroendocrine pathogenesis and redefinition of natural history. Nat. Rev. Endocrinol. 12, 606–615 ( 2016 ) .
  107. 107. Laureti, S. et aluminum. x-linked adrenoleukodystrophy is a frequent causal agent of idiopathic Addison ’ randomness disease in youthful adult male patients. J. Clin. Endocrinol. Metab. 81, 470–474 ( 1996 ) .
  108. 108. Bezman, L. & Moser, H. W. Incidence of x-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am. J. Med. Genet. 76, 415–419 ( 1998 ) .
  109. 109. Hannah-Shmouni, F. & Stratakis, C. A. An overview of connatural errors of metamorphosis manifesting with primary adrenal gland insufficiency. Rev. Endocr. Metab. Disord. 19, 53–67 ( 2018 ) .
  110. 110. Narumi, S. Rare monogenic causes of basal adrenal insufficiency. Curr. Opin. Endocrinol. Diabetes Obes. 25, 172–177 ( 2018 ) .
  111. 111. Tanriverdi, F. et aluminum. Pituitary dysfunction after traumatic mind wound : a clinical and pathophysiological overture. Endocr. Rev. 36, 305–342 ( 2015 ) .
  112. 112. Gubbi, S., Hannah-Shmouni, F., Stratakis, C. A. & Koch, C. A. Primary hypophysitis and early autoimmune disorders of the sellar and suprasellar regions. Rev. Endocr. Metab. Disord. 19, 335–347 ( 2018 ) .
  113. 113. Faje, A. Immunotherapy and hypophysitis : clinical presentation, treatment, and biological insights. Pituitary 19, 82–92 ( 2016 ) .
  114. 114. Caturegli, P. et alabama. Autoimmune hypophysitis. Endocr. Rev. 26, 599–614 ( 2005 ) .
  115. 115. AbdelRazek, M. A., Venna, N. & Stone, J. H. IgG4-related disease of the cardinal and peripheral nervous systems. Lancet Neurol. 17, 183–192 ( 2018 ) .
  116. 116. Lamprecht, A., Sorbello, J., Jang, C., Torpy, D. J. & Inder, W. J. Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. Eur. J. Endocrinol. 179, 353–362 ( 2018 ) .
  117. 117. Fraser, L. A. et aluminum. oral opioids for chronic non-cancer pain : higher prevalence of hypogonadism in men than in women. Exp. Clin. Endocrinol. Diabetes 117, 38–43 ( 2009 ) .
  118. 118. Fountas, A., Van Uum, S. & Karavitaki, N. Opioid-induced endocrinopathies. Lancet Diabetes Endocrinol. 8, 68–80 ( 2020 ) .
  119. 119. Pekic, S. & Popovic, V. Diagnosis of endocrine disease : expanding the lawsuit of hypopituitarism. Eur. J. Endocrinol. 176, R269–R282 ( 2017 ) .
  120. 120. Higham, C. E., Johannsson, G. & Shalet, S. M. Hypopituitarism. Lancet 388, 2403–2415 ( 2016 ) .
  121. 121. Wu, W. et aluminum. Mutations in PROP1 cause familial combined pituitary hormone lack. Nat. Genet. 18, 147–149 ( 1998 ) .
  122. 122. Jullien, N. et alabama. clinical lessons learned in built-in hypopituitarism from two decades of feel in a large international cohort. Clin. Endocrinol. 94, 277–289 ( 2021 ) .
  123. 123. Tutunculer, F., Saka, N., Arkaya, S. C., Abbasoglu, S. & Bas, F. Evaluation of adrenomedullary function in patients with congenital adrenal hyperplasia. Horm. Res. 72, 331–336 ( 2009 ) .
  124. 124. Morita, S. et aluminum. Reduced epinephrine reserve in response to insulin-induced hypoglycemia in patients with pituitary adenoma. Eur. J. Endocrinol. 157, 265–270 ( 2007 ) .
  125. 125. Merke, D. P. et alabama. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase insufficiency. N. Engl. J. Med. 343, 1362–1368 ( 2000 ) .
  126. 126. Bornstein, S. R., Breidert, M., Ehrhart-Bornstein, M., Kloos, B. & Scherbaum, W. A. Plasma catecholamines in patients with Addison ’ randomness disease. Clin. Endocrinol. 42, 215–218 ( 1995 ) .
  127. 127. Mpoy, M. & Kolanowski, J. Urinary catecholamine body waste in patients with secondary adrenocortical insufficiency. J. Endocrinol. Invest. 9, 253–255 ( 1986 ) .
  128. 128. Kim, M. S. et alabama. Decreased adrenomedullary function in infants with classical congenital adrenal gland hyperplasia. J. Clin. Endocrinol. Metab. 99, E1597–E1601 ( 2014 ) .
  129. 129. Geiger, A. M., Pitts, K. P., Feldkamp, J., Kirschbaum, C. & Wolf, J. M. Cortisol-dependent stress effects on cell distribution in healthy individuals and individuals suffering from chronic adrenal insufficiency. Brain Behav. Immun. 50, 241–248 ( 2015 ) .
  130. 130. Wurtman, R. J. & Axelrod, J. Control of enzymatic synthesis of epinephrine in the adrenal myelin by adrenal cortical steroids. J. Biol. Chem. 241, 2301–2305 ( 1966 ) .
  131. 131. Ehrhart-Bornstein, M., Hinson, J. P., Bornstein, S. R., Scherbaum, W. A. & Vinson, G. P. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr. Rev. 19, 101–143 ( 1998 ) .
  132. 132. To, T. T. et aluminum. Pituitary-interrenal interaction in zebrafish interrenal electric organ development. Mol. Endocrinol. 21, 472–485 ( 2007 ) .
  133. 133. Weise, M. et aluminum. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in reception to high-intensity practice. J. Clin. Endocrinol. Metab. 89, 591–597 ( 2004 ) .
  134. 134. Elbelt, U., Hahner, S. & Allolio, B. Altered insulin requirement in patients with type 1 diabetes and elementary adrenal insufficiency receiving standard glucocorticoid refilling therapy. Eur. J. Endocrinol. 160, 919–924 ( 2009 ) .
  135. 135. Orentreich, N., Brind, J. L., Rizer, R. L. & Vogelman, J. H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59, 551–555 ( 1984 ) .
  136. 136. Korth-Schutz, S., Levine, L. S. & New, M. I. Serum androgens in normal prepubescent and pubertal children and in children with precocious adrenarche. J. Clin. Endocrinol. Metab. 42, 117–124 ( 1976 ) .
  137. 137. Lebbe, M. et aluminum. The steroid metabolome in the isolated ovarian follicle and its reaction to androgen exposure and antagonism. Endocrinology 158, 1474–1485 ( 2017 ) .
  138. 138. Gleicher, N., Weghofer, A. & Barad, D. H. The function of androgens in follicle maturation and ovulation generalization : acquaintance or enemy of sterility treatment ? Reprod. Biol. Endocrinol. 9, 116 ( 2011 ) .
  139. 139. Lang, K., Burger-Stritt, S. & Hahner, S. Is DHEA substitution beneficial in chronic adrenal gland failure ? Best Pract. Res. Clin. Endocrinol. Metab. 29, 25–32 ( 2015 ) .
  140. 140. Labrie, F. et aluminum. structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. Baillieres Clin. Endocrinol. Metab. 8, 451–474 ( 1994 ) .
  141. 141. Pluchino, N. et aluminum. Neurobiology of DHEA and effects on sex, climate and cognition. J. Steroid Biochem. Mol. Biol. 145, 273–280 ( 2015 ) .
  142. 142. Arlt, W. et aluminum. Dehydroepiandrosterone successor in women with adrenal insufficiency. N. Engl. J. Med. 341, 1013–1020 ( 1999 ). A double-blind clinical study investigating DHEA in women with AI demonstrating improved well-being and sexuality .
  143. 143. Sapolsky, R. M., Romero, L. M. & Munck, A. U. How bash glucocorticoids influence tension responses ? Integrating permissive, suppressive, stimulatory, and preparatory actions. Endocr. Rev. 21, 55–89 ( 2000 ) .
  144. 144. Besse, J. C. & Bass, A. D. Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J. Pharmacol. Exp. Ther. 154, 224–238 ( 1966 ) .
  145. 145. Kalsner, S. Mechanism of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. Circ. Res. 24, 383–395 ( 1969 ) .
  146. 146.

    Prete, A. et aluminum. prevention of adrenal gland crisis : hydrocortisone responses to major stress compared to stress dose hydrocortisone delivery. J. Clin. Endocrinol. Metab. 105, 2262–2274 ( 2020 ). This study provides an evidence base on the steroidogenic response of the adrenal cortex in case of major stress (major trauma, sepsis and combat stress) .

  147. 147. Udelsman, R. et alabama. Adaptation during surgical try. A reevaluation of the role of glucocorticoids. J. Clin. Invest. 77, 1377–1381 ( 1986 ) .
  148. 148. Quinkler, M., Oelkers, W., Remde, H. & Allolio, B. Mineralocorticoid substitution and monitor in primary adrenal insufficiency. Best Pract. Res. Clin. Endocrinol. Metab. 29, 17–24 ( 2015 ) .
  149. 149. Munck, A., Guyre, P. M. & Holbrook, N. J. Physiological functions of glucocorticoids in stress and their relative to pharmacological actions. Endocr. Rev. 5, 25–44 ( 1984 ) .
  150. 150. Besedovsky, H., del Rey, A., Sorkin, E. & Dinarello, C. A. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233, 652–654 ( 1986 ) .
  151. 151. Barber, A. E. et aluminum. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J. Immunol. 150, 1999–2006 ( 1993 ) .
  152. 152. Morrow, L. E., McClellan, J. L., Conn, C. A. & Kluger, M. J. Glucocorticoids change fever and IL-6 responses to psychological try and to lipopolysaccharide. Am. J. Physiol. 264, R1010–R1016 ( 1993 ) .
  153. 153. Koniaris, L. G., Wand, G. & Wright, T. M. TNF mediates a murine model of Addison ’ s crisis. Shock 15, 29–34 ( 2001 ) .
  154. 154. Boonen, E. et alabama. Reduced hydrocortisone metabolism during critical illness. N. Engl. J. Med. 368, 1477–1488 ( 2013 ) .
  155. 155. Husebye, E. S. et aluminum. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 ( 2014 ) .
  156. 156. Buonocore, F., McGlacken-Byrne, S. M., Del Valle, I. & Achermann, J. C. Current insights into adrenal insufficiency in the newborn and young baby. Front. Pediatr. 8, 619041 ( 2020 ) .
  157. 157. Saevik, A. B. et alabama. Clues for early detection of autoimmune Addison ’ s disease – myths and realities. J. Intern. Med. 283, 190–199 ( 2018 ) .
  158. 158. El-Farhan, N. et alabama. Method-specific serum hydrocortisone responses to the adrenocorticotropic hormone quiz : comparison of boast chromatography-mass spectroscopy and five automated immunoassays. Clin. Endocrinol. 78, 673–680 ( 2013 ) .
  159. 159. Ueland, G. A. et aluminum. The abruptly cosyntropin test revisited : new normal citation range using LC-MS/MS. J. Clin. Endocrinol. Metab. 103, 1696–1703 ( 2018 ) .
  160. 160. Dickstein, G. et alabama. Adrenocorticotropin stimulation test : effects of basal hydrocortisone level, time of sidereal day, and suggested raw sensitive low dose test. J. Clin. Endocrinol. Metab. 72, 773–778 ( 1991 ) .
  161. 161. May, M. E. & Carey, R. M. Rapid adrenocorticotropic hormone test in practice. retrospective review. Am. J. Med. 79, 679–684 ( 1985 ) .
  162. 162. Oelkers, W. The character of high- and low-dose adrenocorticotropic hormone tests in the diagnosis of secondary coil adrenal insufficiency. Eur. J. Endocrinol. 139, 567–570 ( 1998 ) .
  163. 163. Lutz, A. et alabama. adrenocortical function in patients with macrometastases of the adrenal gland gland. Eur. J. Endocrinol. 143, 91–97 ( 2000 ) .
  164. 164. Mao, J. J., Dages, K. N., Suresh, M. & Bancos, I. presentation, disease progress and outcomes of adrenal gland metastases. Clin. Endocrinol. 93, 546–554 ( 2020 ) .
  165. 165. Petersenn, S., Honegger, J. & Quinkler, M. National German audit of diagnosis, treatment, and teaching in secondary adrenal insufficiency. Horm. Metab. Res. 49, 580–588 ( 2017 ) .
  166. 166. Schmidt, I. L., Lahner, H., Mann, K. & Petersenn, S. Diagnosis of adrenal insufficiency : evaluation of the corticotropin-releasing hormone test and basal serum hydrocortisone in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J. Clin. Endocrinol. Metab. 88, 4193–4198 ( 2003 ) .
  167. 167. Grossman, A. B. The diagnosis and management of central addison’s disease. J. Clin. Endocrinol. Metab. 95, 4855–4863 ( 2010 ) .
  168. 168. Erturk, E., Jaffe, C. A. & Barkan, A. L. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia trial. J. Clin. Endocrinol. Metab. 83, 2350–2354 ( 1998 ) .
  169. 169. Hurel, S. J. et alabama. The abruptly Synacthen and insulin stress tests in the appraisal of the hypothalamic-pituitary-adrenal axis. Clin. Endocrinol. 44, 141–146 ( 1996 ) .
  170. 170. Reynolds, R. M., Stewart, P. M., Seckl, J. R. & Padfield, P. L. Assessing the HPA axis in patients with pituitary disease : a UK survey. Clin. Endocrinol. 64, 82–85 ( 2006 ) .
  171. 171. Mukherjee, J. J. et aluminum. A comparison of the insulin tolerance/glucagon test with the unretentive ACTH foreplay test in the appraisal of the hypothalamo-pituitary-adrenal bloc in the early post-operative time period after hypophysectomy. Clin. Endocrinol. 47, 51–60 ( 1997 ) .
  172. 172. Ospina, N. S. et alabama. ACTH stimulation tests for the diagnosis of adrenal insufficiency : taxonomic review and meta-analysis. J. Clin. Endocrinol. Metab. 101, 427–434 ( 2016 ) .
  173. 173. Steiner, H., Bahr, V., Exner, P. & Oelkers, P. W. Pituitary function tests : comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test. Exp. Clin. Endocrinol. 102, 33–38 ( 1994 ) .
  174. 174. Berneis, K. et alabama. combine foreplay of adrenocorticotropic hormone and compound-S by single dose metyrapone quiz as an outpatient operation to assess hypothalamic-pituitary-adrenal function. J. Clin. Endocrinol. Metab. 87, 5470–5475 ( 2002 ) .
  175. 175. Giordano, R. et alabama. Hypothalamus-pituitary-adrenal bloc evaluation in patients with hypothalamo-pituitary disorders : comparison of unlike provocative tests. Clin. Endocrinol. 68, 935–941 ( 2008 ) .
  176. 176. Hamrahian, A. H. et aluminum. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults : results from a prospective randomized multicenter survey. Pituitary 19, 332–341 ( 2016 ) .
  177. 177. Deutschbein, T., Unger, N., Mann, K. & Petersenn, S. Diagnosis of secondary adrenal gland insufficiency in patients with hypothalamic-pituitary disease : comparison between serum and salivary hydrocortisone during the high-dose shortstop synacthen test. Eur. J. Endocrinol. 160, 9–16 ( 2009 ) .
  178. 178. Debono, M. et alabama. Salivary cortisone reflects hydrocortisone exposure under physiological conditions and after hydrocortisone. J. Clin. Endocrinol. Metab. 101, 1469–1477 ( 2016 ) .
  179. 179. Thil ’ en, A. et alabama. Benefits of neonatal shield for congenital adrenal hyperplasia ( 21-hydroxylase insufficiency ) in Sweden. Pediatrics 101, E11 ( 1998 ) .
  180. 180. Kishore Kumar, R., Das, H. & Kini, P. Newborn screening for congenital adrenal hyperplasia in India : what do we need to watch out for ? J. Obstet. Gynaecol. India 66, 415–419 ( 2016 ) .
  181. 181. Yanase, T. et aluminum. Diagnosis and discussion of adrenal insufficiency including adrenal gland crisis : a Japan Endocrine Society clinical practice guideline [ Opinion ]. Endocr. J. 63, 765–784 ( 2016 ) .
  182. 182. Woodcock, T. et alabama. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal gland insufficiency : guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. Anaesthesia 75, 654–663 ( 2020 ) .
  183. 183. Grossman, A., Johannsson, G., Quinkler, M. & Zelissen, P. Therapy of endocrine disease : perspectives on the management of adrenal insufficiency : clinical insights from across Europe. Eur. J. Endocrinol. 169, R165–R175 ( 2013 ) .
  184. 184. Debono, M. et aluminum. Modified-release hydrocortisone to provide circadian hydrocortisone profiles. J. Clin. Endocrinol. Metab. 94, 1548–1554 ( 2009 ) .
  185. 185. Hahner, S. et aluminum. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912–3922 ( 2007 ). A cross-sectional study showing that patients with AI on current standard replacement suffer from significantly impaired health-related subjective health status, irrespective of origin of disease or concomitant disease .
  186. 186. Johannsson, G. et alabama. Improved hydrocortisone exposure-time profile and consequence in patients with adrenal insufficiency : a prospective randomized test of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 ( 2012 ). A randomized trial comparing thrice-daily conventional hydrocortisone replacement with once-daily dual-release hydrocortisone .
  187. 187. european Medicines Agency. Summary of Product Characteristics : Plenadren. hypertext transfer protocol : //www.ema.europa.eu/en/medicines/human/EPAR/plenadren ( 2018 ) .
  188. 188. Giordano, R. et aluminum. improvement of anthropometric and metabolic parameters, and choice of life following treatment with dual-release hydrocortisone in patients with Addison ’ second disease. Endocrine 51, 360–368 ( 2016 ) .
  189. 189. Quinkler, M., Miodini Nilsen, R., Zopf, K., Ventz, M. & Oksnes, M. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 ( 2015 ) .
  190. 190. Isidori, A. M. et alabama. effect of once-daily, modified-release hydrocortisone versus criterion glucocorticoid therapy on metamorphosis and natural immunity in patients with adrenal insufficiency ( DREAM ) : a single-blind, randomised controlled test. Lancet Diabetes Endocrinol. 6, 173–185 ( 2018 ) .
  191. 191. Whittle, E. & Falhammar, H. Glucocorticoid regimens in the treatment of congenital adrenal gland hyperplasia : a taxonomic revue and meta-analysis. J. Endocr. Soc. 3, 1227–1245 ( 2019 ) .
  192. 192. Lovas, K. & Husebye, E. S. Continuous hypodermic hydrocortisone infusion in Addison ’ second disease. Eur. J. Endocrinol. 157, 109–112 ( 2007 ) .
  193. 193. Gagliardi, L. et alabama. Continuous hypodermic hydrocortisone infusion therapy in Addison ’ mho disease : a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 99, 4149–4157 ( 2014 ) .
  194. 194. Nella, A. A. et alabama. A phase 2 study of continuous hypodermic hydrocortisone infusion in adults with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 101, 4690–4698 ( 2016 ) .
  195. 195. Whitaker, M. et alabama. An oral multiparticulate, modified-release, hydrocortisone surrogate therapy that provides physiologic hydrocortisone exposure. Clin. Endocrinol. 80, 554–561 ( 2014 ) .
  196. 196. Mallappa, A. et alabama. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the discussion of adults with authoritative congenital adrenal gland hyperplasia. J. Clin. Endocrinol. Metab. 100, 1137–1145 ( 2015 ). Phase II study investigating the modified-release hydrocortisone formulation Chronocort in 16 adults with classic congenital adrenal hyperplasia. Twice-daily Chronocort induced cortisol profiles similar to physiological cortisol secretion .
  197. 197. Merke, D. P. et alabama. A phase 3 learn of a modified-release hydrocortisone in the treatment of congenital adrenal gland hyperplasia [ abstract OR25-02 ]. J. Endocr. Soc. 4 ( Suppl. 1 ), A107–A108 ( 2020 ) .
  198. 198. Turcu, A. F. et aluminum. Single-dose analyze of a corticotropin-releasing agent receptor-1 antagonist in women with 21-hydroxylase lack. J. Clin. Endocrinol. Metab. 101, 1174–1180 ( 2016 ) .
  199. 199. Saevik, A. B. et alabama. remainder corticosteroid production in autoimmune Addison disease. J. Clin. Endocrinol. Metab. 105, 2430–2441 ( 2020 ) .
  200. 200. Pofi, R. et alabama. Plasma renin measurements are unrelated to mineralocorticoid surrogate dose in patients with chief adrenal insufficiency. J. Clin. Endocrinol. Metab. 105, 314–326 ( 2020 ) .
  201. 201. Oelkers, W., Diederich, S. & Bahr, V. Diagnosis and therapy surveillance in Addison ’ randomness disease : rapid adrenocorticotropic hormone ( ACTH ) test and measurement of plasma ACTH, renin natural process, and aldosterone. J. Clin. Endocrinol. Metab. 75, 259–264 ( 1992 ) .
  202. 202. Schultebraucks, K., Wingenfeld, K., Otte, C. & Quinkler, M. The character of fludrocortisone in cognition and mood in patients with primary coil adrenal insufficiency ( Addison ’ south disease ). Neuroendocrinology 103, 315–320 ( 2016 ) .
  203. 203. Esposito, D., Pasquali, D. & Johannsson, G. Primary adrenal insufficiency : cope mineralocorticoid successor therapy. J. Clin. Endocrinol. Metab. 103, 376–387 ( 2018 ) .
  204. 204. Flad, T. M., Conway, J. D., Cunningham, S. K. & McKenna, T. J. The function of plasma renin activity in evaluating the adequacy of mineralocorticoid refilling in elementary adrenal gland insufficiency. Clin. Endocrinol. 45, 529–534 ( 1996 ) .
  205. 205. Cohen, N., Gilbert, R., Wirth, A., Casley, D. & Jerums, G. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid refilling in Addison ’ randomness disease. J. Clin. Endocrinol. Metab. 81, 1411–1415 ( 1996 ) .
  206. 206. Oelkers, W. & L ’ Age, M. Control of mineralocorticoid substitution in Addison ’ s disease by plasma renin measurement. Klin. Wochenschr. 54, 607–612 ( 1976 ) .
  207. 207. Smith, S. J. et aluminum. attest that patients with Addison ’ sulfur disease are undertreated with fludrocortisone. Lancet 1, 11–14 ( 1984 ) .
  208. 208. Chortis, V. et alabama. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen substitution. J. Clin. Endocrinol. Metab. 98, 161–171 ( 2013 ) .
  209. 209. Johannsson, G. et aluminum. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women : a placebo-controlled test. J. Clin. Endocrinol. Metab. 87, 2046–2052 ( 2002 ) .
  210. 210. Lovas, K. et alabama. substitution of dehydroepiandrosterone in adrenal gland failure : no benefit for subjective health status and sex in a 9-month, randomized, parallel group clinical test. J. Clin. Endocrinol. Metab. 88, 1112–1118 ( 2003 ) .
  211. 211. van Thiel, S. W. et aluminum. Effects of dehydroepiandrostenedione, superimposed on emergence hormone substitution, on quality of biography and insulin-like growth divisor I in patients with junior-grade adrenal insufficiency : a randomized, placebo-controlled, cross-over trial. J. Clin. Endocrinol. Metab. 90, 3295–3303 ( 2005 ) .
  212. 212. Gurnell, E. M. et aluminum. long-run DHEA surrogate in primary adrenal insufficiency : a randomized, controlled test. J. Clin. Endocrinol. Metab. 93, 400–409 ( 2008 ) .
  213. 213. Coles, A. J. et alabama. Dehydroepiandrosterone substitution in patients with Addison ’ mho disease has a bimodal effect on regulative ( CD4+CD25hi and CD4+FoxP3+ ) T cells. Eur. J. Immunol. 35, 3694–3703 ( 2005 ) .
  214. 214. Dhatariya, K., Bigelow, M. L. & Nair, K. S. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 54, 765–769 ( 2005 ) .
  215. 215. Srinivasan, M. et aluminum. effect of dehydroepiandrosterone successor on lipoprotein visibility in hypoadrenal women. J. Clin. Endocrinol. Metab. 94, 761–764 ( 2009 ) .
  216. 216. Callies, F. et alabama. Dehydroepiandrosterone surrogate in women with adrenal insufficiency : effects on body musical composition, serum leptin, bone dollar volume, and drill capacity. J. Clin. Endocrinol. Metab. 86, 1968–1972 ( 2001 ) .
  217. 217. Christiansen, J. J. et alabama. very short term dehydroepiandrosterone treatment in female adrenal gland failure : shock on carbohydrate, lipid and protein metabolism. Eur. J. Endocrinol. 152, 77–85 ( 2005 ) .
  218. 218. Alkatib, A. A. et alabama. A taxonomic review and meta-analysis of randomize placebo-controlled trials of DHEA treatment effects on choice of life in women with adrenal gland insufficiency. J. Clin. Endocrinol. Metab. 94, 3676–3681 ( 2009 ). Meta-analysis of randomized trials of DHEA in AI showing overall small effects of DHEA on quality of life parameters and sexuality .
  219. 219. Allolio, B., Arlt, W. & Hahner, S. DHEA : why, when, and how much–DHEA substitution in adrenal insufficiency. Ann. Endocrinol. 68, 268–273 ( 2007 ). Comprehensive reflection of available evidence on adrenal crisis and discussion of future directions .
  220. 220. Lovas, K. et alabama. Glucocorticoid successor therapy and pharmacogenetics in Addison ’ s disease : effects on bone. Eur. J. Endocrinol. 160, 993–1002 ( 2009 ) .
  221. 221. Koetz, K. R., Ventz, M., Diederich, S. & Quinkler, M. Bone mineral density is not importantly reduced in adult patients on low-dose glucocorticoid surrogate therapy. J. Clin. Endocrinol. Metab. 97, 85–92 ( 2012 ). Systematic assessment of BMD in 122 patients with AI demonstrating normal BMD values on low glucocorticoid replacement doses .
  222. 222. Schulz, J. et alabama. reduction in daily hydrocortisone dose improves bone health in chief adrenal gland insufficiency. Eur. J. Endocrinol. 174, 531–538 ( 2016 ) .
  223. 223. Bjornsdottir, S. et aluminum. risk of hip fracture in Addison ’ mho disease : a population-based cohort report. J. Intern. Med. 270, 187–195 ( 2011 ) .
  224. 224. Ragnarsson, O., Nystrom, H. F. & Johannsson, G. Glucocorticoid substitute therapy is independently associated with dilute bone mineral density in women with hypopituitarism. Clin. Endocrinol. 76, 246–252 ( 2012 ) .
  225. 225. Mo, D. et alabama. fault risk in adult patients treated with growth hormone refilling therapy for growth hormone lack : a prospective experimental age group study. Lancet Diabetes Endocrinol. 3, 331–338 ( 2015 ) .
  226. 226. Mazziotti, G. et alabama. management of endocrine disease : hazard of overtreatment in patients with adrenal gland insufficiency : current and issue aspects. Eur. J. Endocrinol. 177, R231–R248 ( 2017 ) .
  227. 227. Falhammar, H., Filipsson Nystrom, H., Wedell, A., Brismar, K. & Thoren, M. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal gland hyperplasia. Eur. J. Endocrinol. 168, 331–341 ( 2013 ) .
  228. 228. Guarnotta, V., Ciresi, A., Pillitteri, G. & Giordano, C. Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment : a 36-month retrospective analysis. Clin. Endocrinol. 88, 665–672 ( 2018 ) .
  229. 229. Plat, L. et alabama. metabolic effects of short-run elevations of plasma hydrocortisone are more marked in the flush than in the dawn. J. Clin. Endocrinol. Metab. 84, 3082–3092 ( 1999 ). This study showed that elevations of evening cortisol levels could contribute to alterations in glucose tolerance, insulin sensitivity and insulin secretion .
  230. 230. Filipsson, H., Monson, J. P., Koltowska-Haggstrom, M., Mattsson, A. & Johannsson, G. The impact of glucocorticoid refilling regimens on metabolic result and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954–3961 ( 2006 ). Large Swedish cohort–control study revealing increased risk of ischaemic heart disease with increasing steroid replacement dose in women with autoimmune Addison disease. No increase in cerebrovascular disease risk was detected .
  231. 231. Skov, J., Sundstrom, A., Ludvigsson, J. F., Kampe, O. & Bensing, S. Sex-specific hazard of cardiovascular disease in autoimmune Addison disease–a population-based cohort study. J. Clin. Endocrinol. Metab. 104, 2031–2040 ( 2019 ) .
  232. 232. Falhammar, H. et aluminum. Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase lack : a swedish population-based national cohort learn. J. Clin. Endocrinol. Metab. 100, 3520–3528 ( 2015 ) .
  233. 233. Quinkler, M. et aluminum. prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr. Connect. 6, 1–8 ( 2017 ) .
  234. 234. Han, T. S. et aluminum. quality of life in adults with congenital adrenal gland hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance : United Kingdom Congenital adrenal gland Hyperplasia Adult Study Executive ( CaHASE ). Eur. J. Endocrinol. 168, 887–893 ( 2013 ) .
  235. 235. Han, T. S. et aluminum. Glucocorticoid discussion regimen and health outcomes in adults with congenital adrenal gland hyperplasia. Clin. Endocrinol. 78, 197–203 ( 2013 ) .
  236. 236. Behan, L. A. et alabama. Low-dose hydrocortisone replacement is associated with improved arterial awkwardness index and rake pressure dynamics in hard adrenocorticotrophin-deficient hypopituitary male patients. Eur. J. Endocrinol. 174, 791–799 ( 2016 ) .
  237. 237. Werumeus Buning, J. et alabama. Effects of hydrocortisone on the rule of blood pressure : results from a randomized controlled test. J. Clin. Endocrinol. Metab. 101, 3691–3699 ( 2016 ) .
  238. 238. Ventura, M. et alabama. The spectrum of pediatric adrenal gland insufficiency : insights from 34 years of know. J. Pediatr. Endocrinol. Metab. 32, 721–726 ( 2019 ) .
  239. 239. Sterns, R. H. Disorders of plasma sodium–causes, consequences, and correction. N. Engl. J. Med. 372, 55–65 ( 2015 ) .
  240. 240. Kampmeyer, D., Lehnert, H., Moenig, H., Haas, C. S. & Harbeck, B. A hard indigence for improving the education of physicians on glucocorticoid successor treatment in adrenal gland insufficiency : an interdisciplinary and multicentre evaluation. Eur. J. Intern. Med. 33, e13–e15 ( 2016 ) .
  241. 241. Harbeck, B. et alabama. Glucocorticoid surrogate therapy in adrenal insufficiency–a challenge to physicians ? Endocr. J. 62, 463–468 ( 2015 ) .
  242. 242. Hahner, S., Burger-Stritt, S. & Allolio, B. Subcutaneous hydrocortisone administration for hand brake manipulation in adrenal gland insufficiency. Eur. J. Endocrinol. 169, 147–154 ( 2013 ) .
  243. 243. Burger-Stritt, S., Bachmann, L., Kurlbaum, M. & Hahner, S. Emergency treatment of adrenal crisis with prednisone suppositories : a bioequivalence study in female patients with Addison ’ randomness disease. Endocr. Connect. 8, 425–434 ( 2019 ) .
  244. 244. Andela, C. D. et aluminum. timbre of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dose, than with long-run systemic hydrocortisone levels. Psychoneuroendocrinology 72, 80–86 ( 2016 ) .
  245. 245. Lovas, K., Loge, J. H. & Husebye, E. S. Subjective health status in norwegian patients with Addison ’ s disease. Clin. Endocrinol. 56, 581–588 ( 2002 ). This is the first systematic assessment of subjective health status in a large cohort of patients with primary adrenal insufficiency .
  246. 246. Forss, M., Batcheller, G., Skrtic, S. & Johannsson, G. Current commit of glucocorticoid refilling therapy and patient-perceived health outcomes in adrenal insufficiency – a cosmopolitan patient survey. BMC Endocr. Disord. 12, 8 ( 2012 ) .
  247. 247. Kluger, N. et aluminum. afflicted health-related quality of life in Addison ’ s disease–impact of substitution therapy, comorbidities and socio-economic factors. Clin. Endocrinol. 81, 511–518 ( 2014 ) .
  248. 248. Tiemensma, J. et aluminum. psychological morbidity and afflicted choice of biography in patients with stable treatment for primary adrenal gland insufficiency : cross-sectional report and review of the literature. Eur. J. Endocrinol. 171, 171–182 ( 2014 ) .
  249. 249. Ragnarsson, O. et aluminum. The relationship between glucocorticoid substitution and quality of life in 2737 hypopituitary patients. Eur. J. Endocrinol. 171, 571–579 ( 2014 ) .
  250. 250. Oksnes, M. et aluminum. timbre of life in european patients with Addison ’ s disease : robustness of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 ( 2012 ) .
  251. 251. Burger-Stritt, S., Pulzer, A. & Hahner, S. Quality of life and life anticipation in patients with adrenal gland insufficiency : what is true and what is urban myth ? Front. Horm. Res. 46, 171–183 ( 2016 ) .
  252. 252. Bleicken, B. et aluminum. Impaired immanent health condition in chronic adrenal insufficiency : affect of different glucocorticoid successor regimens. Eur. J. Endocrinol. 159, 811–817 ( 2008 ) .
  253. 253. Bleicken, B. et aluminum. determine of hydrocortisone dose dodge on health-related choice of life in patients with adrenal insufficiency. Clin. Endocrinol. 72, 297–304 ( 2010 ) .
  254. 254. Oksnes, M. et aluminum. Continuous hypodermic hydrocortisone infusion versus oral hydrocortisone replacement for discussion of Addison ’ s disease : a randomized clinical trial. J. Clin. Endocrinol. Metab. 99, 1665–1674 ( 2014 ). Randomized clinical trial comparing continuous subcutaneous hydrocortisone infusion with conventional oral hydrocortisone in 33 patients with Addison disease showing more improvement in some quality of life parameters under more physiological cortisol profiles .
  255. 255. Nilsson, A. G. et alabama. long-run safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency : a phase 3b, open-label, extension survey. Eur. J. Endocrinol. 176, 715–725 ( 2017 ) .
  256. 256. Bancos, I. et aluminum. primary coil adrenal insufficiency is associated with impaired natural killer whale cell function : a potential connect to increased mortality. Eur. J. Endocrinol. 176, 471–480 ( 2017 ). Analysis of 42 patients with primary AI showing normal neutrophil function but significantly decreased cytotoxicity of natural killer cells which potentially compromises antiviral immune defence .
  257. 257. Smans, L. C., Souverein, P. C., Leufkens, H. G., Hoepelman, A. I. & Zelissen, P. M. Increased practice of antimicrobial agents and hospital admission for infections in patients with primary adrenal gland insufficiency : a cohort study. Eur. J. Endocrinol. 168, 609–614 ( 2013 ) .
  258. 258. Tresoldi, A. S. et aluminum. Increased infection gamble in Addison ’ south disease and congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 105, 418–429 ( 2020 ) .
  259. 259. Gan, E. H. & Pearce, S. H. Management of hormone disease : regenerative therapies in autoimmune Addison ’ randomness disease. Eur. J. Endocrinol. 176, R123–R135 ( 2017 ) .
  260. 260. Balyura, M. et alabama. transplant of bovine adrenocortical cells encapsulated in alginate. Proc. Natl Acad. Sci. USA 112, 2527–2532 ( 2015 ) .
  261. 261. Gan, E. H. et aluminum. remainder adrenal function in autoimmune Addison ’ mho disease : improvement after tetracosactide ( ACTH1-24 ) discussion. J. Clin. Endocrinol. Metab. 99, 111–118 ( 2014 ) .
  262. 262. Pearce, S. H. et alabama. adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison ’ randomness disease. J. Clin. Endocrinol. Metab. 97, E1927–E1932 ( 2012 ) .
  263. 263. Napier, C. et aluminum. remainder adrenal function in autoimmune Addison ’ s disease – impression of dual therapy with rituximab and storehouse tetracosactide. J. Clin. Endocrinol. Metab. 105, e1250–e1259 ( 2020 ) .
  264. 264. Hahner, S. et alabama. Timelines in the management of adrenal gland crisis – targets, limits and reality. Clin. Endocrinol. 82, 497–502 ( 2015 ) .
  265. 265. Burger-Stritt, S. et aluminum. management of adrenal gland emergencies in educated patients with adrenal gland insufficiency–a prospective learn. Clin. Endocrinol. 89, 22–29 ( 2018 ) .
  266. 266. Repping-Wuts, H. J., Stikkelbroeck, N. M., Noordzij, A., Kerstens, M. & Hermus, A. R. A glucocorticoid department of education group meeting : an effective strategy for improving self-management to prevent adrenal gland crisis. Eur. J. Endocrinol. 169, 17–22 ( 2013 ) .
  267. 267. Burger-Stritt, S. et alabama. standardized affected role department of education in adrenal insufficiency – a prospective multi-centre evaluation. Eur. J. Endocrinol. 183, 119–127 ( 2020 ). This longitudinal, prospective, questionnaire-based, multicentre study included 526 patients with AI and proved that group education of patients with chronic AI represents a helpful tool for the guidance of patients, their self-assurance and their knowledge on prevention of adrenal crises .
  268. 268. Quinkler, M., Hahner, S., Johannsson, G. & Stewart, P. M. Saving lives of patients with adrenal gland insufficiency : a pan-European inaugural ? Clin. Endocrinol. 80, 319–321 ( 2014 ) .
  269. 269. Bornstein, S. R., Bornstein, T. D. & Andoniadou, C. L. Novel medications inducing adrenal gland insufficiency. Nat. Rev. Endocrinol. 15, 561–562 ( 2019 ) .
  270. 270. Nicolaides, N. C., Chrousos, G. P. & Charmandari, E. in Endotext ( eds Feingold, K. R. et alabama ) ( MDText.com, Inc, 2000 ) .
  271. 271. Mah, P. M. et aluminum. Weight-related dose, time and monitoring hydrocortisone surrogate therapy in patients with adrenal insufficiency. Clin. Endocrinol. 61, 367–375 ( 2004 ) .
  272. 272. Bratland, E. & Husebye, E. S. Cellular exemption and immunopathology in autoimmune Addison ’ south disease. Mol. Cell Endocrinol. 336, 180–190 ( 2011 ) .
  273. 273. Rege, J., Turcu, A. F., Else, T., Auchus, R. J. & Rainey, W. E. Steroid biomarkers in homo adrenal disease. J. Steroid Biochem. Mol. Biol. 190, 273–280 ( 2019 ) .
  274. 274. Mannstadt, M. et aluminum. Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 ( 2017 ) .
  275. 275. Lebbe, M. & Arlt, W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy ? Clin. Endocrinol. 78, 497–502 ( 2013 ) .
  276. 276. Erichsen, M. M., Husebye, E. S., Michelsen, T. M., Dahl, A. A. & Lovas, K. Sexuality and birthrate in women with Addison ’ s disease. J. Clin. Endocrinol. Metab. 95, 4354–4360 ( 2010 ) .
  277. 277. Remde, H., Zopf, K., Schwander, J. & Quinkler, M. Fertility and pregnancy in primary adrenal insufficiency in Germany. Horm. Metab. Res. 48, 306–311 ( 2016 ) .
  278. 278. Bjornsdottir, S. et alabama. Addison ’ s disease in women is a risk factor for an adverse pregnancy result. J. Clin. Endocrinol. Metab. 95, 5249–5257 ( 2010 ) .
  279. 279. Schneiderman, M., Czuzoj-Shulman, N., Spence, A. R. & Abenhaim, H. A. Maternal and neonatal outcomes of pregnancies in women with Addison ’ s disease : a population-based cohort learn on 7.7 million births. BJOG 124, 1772–1779 ( 2017 ) .
  280. 280. Bothou, C. et alabama. current management and consequence of pregnancies in women with adrenal insufficiency : experience from a multicenter survey. J. Clin. Endocrinol. Metab. 105, e2853–e2863 ( 2020 ). Large retrospective multicentre analysis of the course of pregnancy in women with adrenal insufficiency .
  281. 281. Hirschberg, A. L. et alabama. generative and perinatal outcomes in women with congenital adrenal gland hyperplasia : a population-based cohort study. J. Clin. Endocrinol. Metab. 106, e957–e965 ( 2021 ) .
  282. 282. Quinkler, M. et aluminum. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. Eur. J. Endocrinol. 146, 789–799 ( 2002 ) .
  283. 283. Quinkler, M., Meyer, B., Oelkers, W. & Diederich, S. Renal inactivation, mineralocorticoid generation, and 11β-hydroxysteroid dehydrogenase inhibition ameliorate the antimineralocorticoid effect of progesterone in vivo. J. Clin. Endocrinol. Metab. 88, 3767–3772 ( 2003 ) .
  284. 284. Cosimo, C. & Franco, C. Addison ’ s disease and pregnancy : case composition. J. Prenat. Med. 3, 53–54 ( 2009 ) .
  285. 285. Oelkers, W. K. Effects of estrogens and progestogens on the renin-aldosterone arrangement and rake coerce. Steroids 61, 166–171 ( 1996 ) .
  286. 286. Stirrat, L. I. et alabama. transmit and metamorphosis of hydrocortisone by the isolate suffuse human placenta. J. Clin. Endocrinol. Metab. 103, 640–648 ( 2018 ) .
  287. 287. Coursin, D. B. & Wood, K. E. Corticosteroid supplement for adrenal insufficiency. JAMA 287, 236–240 ( 2002 ) .
  288. 288. Li, D. et alabama. Determinants of self-reported health outcomes in adrenal gland insufficiency : a multi-site survey study. J. Clin. Endocrinol. Metab. hypertext transfer protocol : //doi.org/10.1210/clinem/dgaa668 ( 2020 ) .
  289. 289.

    Read more: ED

    Fleming, L., Knafl, K., Knafl, G. & Van Riper, M. Parental management of adrenal gland crisis in children with congenital adrenal hyperplasia. J. Spec. Pediatr. Nurs. 22, e12190 ( 2017 ) .

  290. 290. Kienitz, T., Hahner, S., Burger-Stritt, S. & Quinkler, M. Therapeutic patient education for adrenal insufficiency under COVID-19 pandemic conditions. Exp. Clin. Endocrinol. Diabetes hypertext transfer protocol : //doi.org/10.1055/a-1217-7208 ( 2020 ) .

Leave a Reply

Your email address will not be published.